Information Provided By:
Fly News Breaks for May 28, 2019
May 28, 2019 | 04:51 EDT
B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $32 from $26 saying he remains bullish on the company;s continued data generation. Mamtani reiterates a Buy rating on the shares.
News For ARWR From the Last 2 Days
There are no results for your query ARWR